Shandong Buchang Pharmaceuticals Co., Ltd.

The company was founded in 2001 and completed the shareholding system reform in 2012. It passed the IPO review by the Securities Regulatory Commission in July 2016 and was successfully listed on November 18, 2016. The company is mainly engaged in R&D, production and sales of proprietary Chinese medicines, and is also entering and expanding in the fields of chemicals, biopharmaceuticals, and vaccines. The company's main products are Brainxintong capsules, Xinxin tablets, Danhong injection, Red Nuclear Medicine, Kang Gynecitis, Prostate Relaxation capsules, Lung Detoxification Granules, Compound Cerebropeptide Injection, Compound Triotide Injection, Gu Hong Injection, Ginkgo Honey Ring Oral Solution, Biopharmaceuticals, and Vaccines. Corporate honors include the “Chinese Manufacturing Champion Enterprise” award, “2017 China Pharmaceutical's Most Socially Responsible Enterprise”, “2017 China Pharmaceutical's Most Growing Product Brand”, and “2017 China Pharmaceutical Investment Association's Top Ten Strategic Cooperation Enterprises”.